Josephine Taverna is an Oncology physician affiliated with The University of Texas at San Antonio. OpenAlex indexes 48 publications with 665 citations (h-index 15); ClinicalTrials.gov lists 1 registered study matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
7979 Wurzbach Rd Fl 4
San Antonio, TX 782294427
Telephone
210-450-1143Registry record last updated 17 Mar 2018.
Clinical trials
- Patient-derived Organoid Model and Circulating Tumor Cells for Treatment Response of Lung Cancer
Sponsor: The University of Texas Health Science Center at San Antonio
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
16 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Janssen Biotech, Inc.Program year202549 payments$50,570openpaymentsdata.cms.gov ↗
- AstraZeneca Pharmaceuticals LPProgram year20251 payment
- Genentech, Inc.Program year20251 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
89.6%PD-1 inhibitor86.4%Pembrolizumab100%Part B, office-administered≥11 patientsNucleoside Metabolic Inhibitor2%Gemcitabine hydrochloride100%Part B, office-administered≥13 patients+ 1 more class in this area
Sensory organs
6.3%Corticosteroid6.3%Dexamethasone sodium phosphate87%Dexamethasone13%Part D + Part B≥21 patientsNervous system
2.2%Phenothiazine0.8%Prochlorperazine Maleate100%Part D≥19 patientsAtypical Antipsychotic0.7%Olanzapine100%Part D≥19 patients+ 2 more classes in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
2 NIH research awards on record, funded 2023–2026 per NIH RePORTER. The latest:
- Targeting mucin-type O-glycosylation for EGFR mutant non-small cell lung cancer
University of Texas Hlth Science Center
FY2026$609,846R01CA300241 - Toward Clinical Trial: AXL-STAT3 Targeting of Lung Tumor Microenvironments
University of Texas Hlth Science Center
FY2026$575,193R01CA269766 - Toward Clinical Trial: AXL-STAT3 Targeting of Lung Tumor Microenvironments
University of Texas Hlth Science Center
FY2025$575,193R01CA269766
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Similar KOLs
Other experts from the same institution or the same specialty.
Minkyu Kim
The University of Texas at San Antonio
Rene Olvera, MD
The University of Texas at San Antonio
S.R. Simon
The University of Texas at San Antonio
Carrie Jo Braden
The University of Texas at San Antonio
Carl June, MD
University of Pennsylvania
Rainer Storb
University of Washington
Christina Fitzmaurice, MD
Larry Norton, MD
Memorial Sloan Kettering Cancer Center
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”